Berlin, 11.02.2022

Today, Focus published an interview with our employee and successfully treated COVID patient Oliver Wenske. He tells in great detail and on behalf of many of us about the process of cognition we had in the course of the pandemic and what his experience with CRP apheresis looks like as one of the first COVID-19 patients treated.

Since the article is written in German, here is a summary of the interview content in English: As a 53-year-old diabetic, Oliver Wenske was lucky in his misfortune when he fell seriously ill with Covid-19. He recently started working for a medical technology company and had the opportunity to undergo a special therapy. Until now, Pentracor GmbH has focused on the treatment of heart attacks and strokes. The company's scientists always say that nature doesn't do anything for free when it comes to the C-reactive protein (CRP). It initiates the disposal of bacteria, but also of inactive or dying endogenous cells. An exciting discovery was made at Pentracor a few years ago, because the protein sometimes causes cells to be disposed of too quickly. This is exactly where the blood washing begins. When Oliver fell ill with Covid-19 towards the end of 2020, he initially had the usual symptoms. The CRP level in the blood was measured twice a day, and it increased every day. This is very unusual in viral diseases, his colleague said. Oliver is grateful that he was treated without further ado. Meanwhile he had a very high fever, shallow breathing and an oxygen saturation of less than 90 percent. After four days connected to devices with the adsorber and a noisy centrifuge, he was completely exhausted. CRP levels continued to be measured. On day one it was 50 milligrams per liter. On the third day at 133 mg/litre. Without the treatment, the value on the third day would certainly have been much higher. This was confirmed by an X-ray. Before the treatment, Oliver had typical striated changes and fluid had accumulated in the lungs. After the treatment it was all gone. After that it slowly went uphill. Oliver was very weak and needed a few months to recover before he could return to full work and his sporting hobbies. Meanwhile, he has no sequelae as subsequent investigations have shown. He explains the long regeneration phase with the loss of muscle mass. The images of his lungs before the start of the blood washing spoke for a severe course. That's why he's happy that he had this opportunity, but also a little bit sad, because a lot of people in a similar situation didn't have or won't have this advantage. Many hospitals first want to have large clinical studies before they embark on a new type of procedure. The whole article in German can be found here: